BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
Globe Newswire•14/10/2026•08:00 ET
0
Key Highlights
- ➤ANA2026 accepted two bezisterim Phase 2 posters covering Parkinson’s disease and Long COVID
- ➤SUNRISE-PD enrolled 57 early Parkinson’s patients, reporting biomarker and clinical improvements versus placebo
- ➤ADDRESS-LC enrolled approximately 200 patients to evaluate bezisterim for Long COVID symptoms
- ➤ADDRESS-LC missed statistical significance across all overall intent-to-treat endpoints
- ➤BioVie reported statistically significant ADDRESS-LC results only in pre-specified subgroup analyses
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company’s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson’s Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Association.
Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026.
Get started
Create a free account to read the full story.